- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BENEVOLENTAI Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 3,670 | 0,00 % | Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note | ||
| ABCELLERA BIOLOGICS | 6,740 | -1,75 % | AbCellera-Aktie mit +11% - Ausbruch liefert Kaufsignal | Die AbCellera-Aktie hat zum Wochenschluss mit einem Kursplus von rund 11% ein starkes Lebenszeichen gesendet. Gleichzeitig gelang der Ausbruch über einen wichtigen charttechnischen Widerstand, wodurch... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 2,347 | +3,71 % | ANAVEX LIFE SCIENCES CORP im stabilen Gleichgewicht | ||
| VERACYTE | 51,44 | +0,12 % | VERACYTE, INC. - 8-K, Current Report | ||
| ASCLETIS PHARMA | 1,200 | +1,69 % | GIC Discloses Third Change in Shareholding in Ascletis Pharma Inc. -B (01672.HK) This Year: Further Increases Stake by Over 10 Million Shares, Raising Holding from 7.00% to 8.36% | HONG KONG, June 26, 2026 - (ACN Newswire) - Recently, Singapore's sovereign wealth fund GIC updated its shareholding data for Ascletis Pharma Inc. -B (01672.HK) once again, marking its third Disclosure... ► Artikel lesen | |
| ABSCI | 11,580 | -0,09 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BIOMEA FUSION | 1,475 | +0,34 % | Biomea Fusion, Inc.: Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights | Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used... ► Artikel lesen | |
| JASPER THERAPEUTICS | 0,419 | -0,45 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value | REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody... ► Artikel lesen | |
| LANTERN PHARMA | 4,160 | -0,24 % | RedChip Companies, Inc.: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers | CEO Panna Sharma to Lead Live, Unscripted Platform Walkthrough in Two Interactive Sessions on April 30, 2026 - Open to Investors, Researchers, and the Global Biomedical CommunityRegistration Link &... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 132,69 | -0,03 % | Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Billion, Camp Mystic Bankruptcy | ||
| ENLIVEN THERAPEUTICS | 50,75 | 0,00 % | Jones Trading raises Enliven Therapeutics price target on CML trials | ||
| CG ONCOLOGY | 71,05 | 0,00 % | Hedge Fund and Insider Trading News: Paul Singer, Warren Buffett, Ray Dalio, George Soros, Millennium Management, Point72 Asset Management, Citadel Investment Group, CG Oncology Inc (CGON), Beam Therapeutics Inc (BEAM), and More | ||
| MINERALYS THERAPEUTICS | 26,980 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 335,02 | +0,07 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,710 | +0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen |
BENEVOLENTAI gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BENEVOLENTAI finden Sie auf Wallstreet Online.